Impact of asundexian on a panel of coagulation assays.

ABSTRACT:

Background

During the last few years, the small, oral, activated factor XI inhibitor, asundexian, has been investigated in different cardiovascular disorders. However, little is known about its impact on laboratory coagulation assays.

Objectives

To describe the effects of asundexian on a panel of laboratory coagulation assays.

Methods

The following assays were performed in normal pooled plasma spiked with increasing concentrations of asundexian (0-2000 ng/mL): activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen quantification (PT-derived and Clauss method), one-stage aPTT and PT-based coagulation factor assays, chronometric protein C and immunoturbidimetric protein S assays, reptilase time, chromogenic ecarin assay, dilute Russell's viper v

SUBMITTER: Vassart J 

PROVIDER: S-EPMC12301727 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature